EP0979292 - GENE CONSTRUCT ENCODING A HETEROLOGOUS PRODRUG-ACTIVATING ENZYME AND A CELL TARGETING MOIETY [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 04.09.2009 Database last updated on 02.09.2024 | Most recent event Tooltip | 30.09.2011 | Lapse of the patent in a contracting state New state(s): CY | published on 02.11.2011 [2011/44] | Applicant(s) | For all designated states AstraZeneca AB 151 85 Södertälje / SE | [2000/35] |
Former [2000/20] | For all designated states AstraZeneca UK Limited 15 Stanhope Gate London W1Y 6LN / GB | ||
Former [2000/07] | For all designated states ZENECA LIMITED 15 Stanhope Gate London W1Y 6LN / GB | Inventor(s) | 01 /
EMERY, Stephen, Charles Zeneca Pharmaceuticals Intell. Property Dept. Mereside, Alderley Park Macclesfield Cheshire SK10 4TG / GB | 02 /
BLAKEY, David, Charles Zeneca Pharmaceuticals Intell. Property Dept. Mereside, Alderley Park Macclesfield Cheshire SK10 4TG / GB | [2000/07] | Representative(s) | Giles, Allen Frank AstraZeneca PLC Global Intellectual Property Mereside Alderley Park Macclesfield, Cheshire SK10 4TG / GB | [N/P] |
Former [2000/07] | Giles, Allen Frank AstraZeneca PLC Global Intellectual Property Mereside Alderley Park Macclesfield, Cheshire SK10 4TG / GB | Application number, filing date | 98919380.0 | 05.05.1998 | [2000/07] | WO1998GB01294 | Priority number, date | GB19970009421 | 10.05.1997 Original published format: GB 9709421 | [2000/07] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO9851787 | Date: | 19.11.1998 | Language: | EN | [1998/46] | Type: | A2 Application without search report | No.: | EP0979292 | Date: | 16.02.2000 | Language: | EN | The application published by WIPO in one of the EPO official languages on 19.11.1998 takes the place of the publication of the European patent application. | [2000/07] | Type: | B1 Patent specification | No.: | EP0979292 | Date: | 29.10.2008 | Language: | EN | [2008/44] | Search report(s) | International search report - published on: | EP | 01.04.1999 | Classification | IPC: | C12N15/62, A61K48/00, // C07K16/28, C12N9/48 | [2000/07] | CPC: |
B82Y5/00 (EP,US);
C12N15/00 (KR);
A61K47/6899 (EP,US);
A61P35/00 (EP);
A61P43/00 (EP);
C07K16/3007 (EP,US);
C12N9/48 (EP,US);
A61K38/00 (EP,US);
A61K48/00 (EP,US);
| Designated contracting states | AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE [2000/07] | Title | German: | GENKONSTRUKT DAS FÜR EIN HETEROLOGES "PRODRUG"-AKTIVIERENDES ENZYM UND FÜR EIN ZELLGERICHTES TEIL KODIERT | [2000/07] | English: | GENE CONSTRUCT ENCODING A HETEROLOGOUS PRODRUG-ACTIVATING ENZYME AND A CELL TARGETING MOIETY | [2000/07] | French: | CONSTRUCTION DE GENE CODANT POUR UNE ENZYME HETEROLOGUE CAPABLE D'ACTIVER UNE PRODROGUE ET UN GROUPEMENT VISANT UNE CELLULE | [2008/20] |
Former [2000/07] | COMPOSES CHIMIQUES | Biological material | This application mentions deposited biological material, check the file for details | Entry into regional phase | 10.12.1999 | National basic fee paid | 10.12.1999 | Designation fee(s) paid | 10.12.1999 | Examination fee paid | Examination procedure | 02.11.1998 | Request for preliminary examination filed International Preliminary Examining Authority: EP | 10.12.1999 | Examination requested [2000/07] | 31.08.2005 | Despatch of a communication from the examining division (Time limit: M06) | 07.03.2006 | Reply to a communication from the examining division | 28.03.2007 | Despatch of a communication from the examining division (Time limit: M06) | 04.09.2007 | Reply to a communication from the examining division | 31.10.2007 | Despatch of a communication from the examining division (Time limit: M02) | 24.12.2007 | Reply to a communication from the examining division | 18.04.2008 | Communication of intention to grant the patent | 17.07.2008 | Fee for grant paid | 17.07.2008 | Fee for publishing/printing paid | Opposition(s) | 30.07.2009 | No opposition filed within time limit [2009/41] | Fees paid | Renewal fee | 15.05.2000 | Renewal fee patent year 03 | 10.05.2001 | Renewal fee patent year 04 | 06.05.2002 | Renewal fee patent year 05 | 07.05.2003 | Renewal fee patent year 06 | 05.05.2004 | Renewal fee patent year 07 | 13.05.2005 | Renewal fee patent year 08 | 27.03.2006 | Renewal fee patent year 09 | 07.05.2007 | Renewal fee patent year 10 | 18.03.2008 | Renewal fee patent year 11 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | AT | 29.10.2008 | BE | 29.10.2008 | CY | 29.10.2008 | DK | 29.10.2008 | FI | 29.10.2008 | NL | 29.10.2008 | GR | 30.01.2009 | PT | 30.03.2009 | IE | 05.05.2009 | LU | 05.05.2009 | MC | 31.05.2009 | [2011/44] |
Former [2011/25] | AT | 29.10.2008 | |
BE | 29.10.2008 | ||
DK | 29.10.2008 | ||
FI | 29.10.2008 | ||
NL | 29.10.2008 | ||
GR | 30.01.2009 | ||
PT | 30.03.2009 | ||
IE | 05.05.2009 | ||
LU | 05.05.2009 | ||
MC | 31.05.2009 | ||
Former [2010/28] | AT | 29.10.2008 | |
BE | 29.10.2008 | ||
DK | 29.10.2008 | ||
FI | 29.10.2008 | ||
NL | 29.10.2008 | ||
PT | 30.03.2009 | ||
IE | 05.05.2009 | ||
MC | 31.05.2009 | ||
Former [2010/05] | AT | 29.10.2008 | |
BE | 29.10.2008 | ||
DK | 29.10.2008 | ||
FI | 29.10.2008 | ||
NL | 29.10.2008 | ||
PT | 30.03.2009 | ||
MC | 31.05.2009 | ||
Former [2009/32] | AT | 29.10.2008 | |
BE | 29.10.2008 | ||
FI | 29.10.2008 | ||
NL | 29.10.2008 | ||
PT | 30.03.2009 | ||
Former [2009/30] | AT | 29.10.2008 | |
FI | 29.10.2008 | ||
NL | 29.10.2008 | ||
PT | 30.03.2009 | Cited in | International search | [X]EP0501215 (BEHRINGWERKE AG [DE]) [X] 1,2,14,15,17 * example - * * claim - *; | [Y]WO9402450 (ZENECA LTD [GB], et al) [Y] 16,18 * claim - *; | [XY]WO9515341 (CANCER RES CAMPAIGN TECH [GB], et al) [X] 1-5,7,8,14,15,17 * example 4 * * claim - * [Y] 6,9,16,18; | [Y]WO9707769 (ZENECA LTD [GB], et al) [Y] 6,9 * example - * * claim - *; | [X] - R. BEGENT ET AL., "Single-chain Fv antibodies for targeting cancer therapy.", BIOCHEMICAL SOCIETY TRANSACTIONS, (199705), vol. 25, no. 2, pages 715 - 717, XP002092530 [X] 1-5,7,8,14,15,17 * the whole document * | [X] - K. BOSSLET ET AL., "Molecular and functional characterisation of a fusion protein suited for tumour specific prodrug activation.", BRITISH JOURNAL OF CANCER, London, GB, (199202), vol. 65, no. 2, pages 234 - 238, XP002092531 [X] 1,2,14,15,17 * the whole document * | [X] - K. BOSSLET ET AL., "Tumor-selective prodrug activation by fusion protein-mediated catalysis.", CANCER RESEARCH, Baltimore, MD, USA, (19940415), vol. 54, no. 8, pages 2151 - 2159, XP002092532 [X] 1,2,14,15,17 * the whole document * | [A] - R. SHERWOOD, "Advanced drug delivery reviews: enzyme prodrug therapy.", ADVANCED DRUG DELIVERY REVIEWS, Amsterdam, The Netherlands, (1996), vol. 22, pages 269 - 288, XP000749297 [A] 1-18 * page 270, column R, line 17 - page 272, column R, line 33 * * page 280, column R, line 24 - line 32 * DOI: http://dx.doi.org/10.1016/S0169-409X(96)00450-4 | [A] - H. SVENSSON ET AL., "Synthesis and characterization of monoclonal antibody-beta-lactamase conjugates.", BIOCONJUGATE CHEMISTRY, Washington, DC, USA, (199405), vol. 5, no. 3, pages 262 - 267, XP000446101 [A] 7,8 * abstract * DOI: http://dx.doi.org/10.1021/bc00027a012 |